The initial rollout of a COVID-19 vaccine in the UK is getting very close indeed. To support this effort, the Government has appointed Nadim Zahawi MP as Minister for Vaccine Deployment in the Department of Health and Social Care (DHSC).
Amid gloomy economic predictions and rising public borrowing fuelled by the pandemic, the Chancellor delivered a one-year government spending settlement with investment in jobs and infrastructure to reassure a nervous nation.
The news that we’ve all been waiting for is out today, from the UK-sourced Oxford University and AstraZeneca COVID-19 vaccine. The great news is that the vaccine works in Phase III clinical trials. For an industry audience it is worth digging into the complex dataset.
Breaking news today that Moderna has released initial data on their mRNA vaccine’s Phase 3 study, which met statistical criteria with a vaccine efficacy of 94.5%. The phase 3 trial was conducted in the US in partnership with BARDA and Operation Warp Speed and based on these interim safety and efficacy data, Moderna intends to submit an application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the coming weeks. It’s great news and following last week’s announcement by Pfizer/Biontech, shows the importance of smaller biotech companies in our innovation ecosystem.
A report published today by the British Business Bank is the most comprehensive analysis of UK life science venture capital performance to date, and it reveals that life science investments have performed equally or better than those in non-life sciences.
The public interest in the development of a successful COVID-19 vaccine has resulted in unprecedented attention for the UK bioprocessing and manufacturing community in 2020. You would be hard pressed to find a day in recent memory where a vaccine and how it will be made has not appeared in the news. The work that companies have done to support the manufacturing capacity required to scale a successful vaccine here in the UK has been extraordinary. In this blog, I explore the benefits and opportunities this presents ahead of the bioProcessUK conference in December.
The UK Government has recently published its formal response to the consultation on changes to the Human Medicine Regulations (HMRs) to support the effective rollout of a COVID-19 vaccine and the upscaling of flu vaccination programme in the UK. This blog post explains the position the BIA took during the expeditated consultation process.